TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32421218
Drug: Ad‐HMN patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad‐HMN patch
Study: 32421218
Drug: Ad‐LMN patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad‐LMN patch
Study: 32205677
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (EX) - combination of heavy and explosive strength and sprint exercises for 20 weeks
Study: 616191717
Drug: Salt-soda solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt-soda solution (SSS)
Study: 86216967
Drug: Pre-operative intravenous
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intravenous infusion cholangiography and selective operative cholangiography (group 2)
Study: 33831803
Drug: Laughter yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laughter yoga (30 min, 16 sessions, twice-weekly)
Study: 33647748
Drug: Porous Plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous Plasma Spray (VP) coated tibial component
Study: 35815916
Drug: Isotretinoin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (20 mg daily) and topical tacrolimus (0.1% BD)
Study: 35815916
Drug: Finasteride (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (2.5 mg daily) and topical tacrolimus (0.1% BD)
Study: 34872140
Drug: Infertility counseling
Normalized name: Tests for fertility disturbances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infertility counseling for 6 sessions (45 minutes each, twice a week)
Study: 33278020
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg daily for 5 days
Study: 33278020
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 mg daily for 5 days
Study: 32564614
Drug: Tiered tax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiered tax (<5 g of added sugar/8 oz: no tax; 5-20 g/8 oz: $0.01/oz; >20 g/8 oz: $0.02/oz)
Study: 34543323
Drug: Steroid intake,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid intake, ileus, acute kidney injury (AKI), metabolic acidosis, hypocalcemia
Study: 35861176
Drug: Non-protein calorie
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-protein calorie supplements (280 kcal/day for 6 months)
Study: 34598781
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose methylprednisolone (MP)
Study: 34598781
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose methylprednisolone (MP) administered at home
Study: 36209047
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of galcanezumab (2 prefilled syringes of 120 mg)
Study: 36209047
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of galcanezumab with conventional preventive therapy
Study: 36209047
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of galcanezumab as initial preventive therapy
Study: 36209047
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of galcanezumab
Study: 36209047
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of galcanezumab therapy add-on conventional preventive therapy
Study: 36209047
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of galcanezumab initial therapy
Study: 34407846
Drug: Supplementation dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation dose of 3 g of vitamin C per day for 96 h
Study: 34407846
Drug: Pharmacological dose
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological dose of 10 g of vitamin C per day for 96 h
Study: 33861768
Drug: Maternal praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal praziquantel (PZQ) treatment
Study: 34702443
Drug: Calcitriol 0.5
Normalized name: CALCITRIOL 0.5MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.5 μg per os twice daily for three days before surgery
Study: 36265502
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg intravenously every 3 weeks for 17 cycles)
Study: 32044505
Drug: PGE1 treatment
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 treatment (intravenous injection)
Study: 36214628
Drug: Therapist-supported acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-supported acceptance and commitment therapy-based bibliotherapy (bi-weekly therapist support)
Study: 35650554
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (load dose 0.5 μg kg−1 over 10 min, followed by maintenance dose 0.2 μg kg−1 h−1)
Study: 34916855
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) administered 2 weeks after fertilization for 6 months
Study: 34916855
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 2 weeks after fertilization for 6 months
Study: 34384282
Drug: Oral maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral maraviroc (MVC) 300 mg dosed orally
Study: 34384282
Drug: MVC 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC 1% gel dosed rectally
Study: 34384282
Drug: MVC 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC 1% gel dosed vaginally
Study: 36200403
Drug: Mailed brochure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailed brochure about BZRA risks and information about a free, online cognitive behavioral therapy for insomnia (CBTI) program (Arm 1)
Study: 36200403
Drug: Mailed brochure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailed brochure without insomnia treatment information (Arm 3)
Study: 35931131
Drug: Vaginal hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal hysterectomy with uterosacral suspension
Study: 33861375
Drug: Prednisolone 1
Normalized name: prednisolone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1 mg/kg/day (low dose)
Study: 33861375
Drug: Prednisolone 2
Normalized name: prednisolone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 2 mg/kg/day (standard dose)
Study: 34724640
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) algorithms - Random Forest Classifier (RFC)
Study: 34716753
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 μg/kg/min as a continuous 24‐h intravenous infusion administered once monthly for 1 year)
Study: 35472247
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention (counselling intervention including drug information and answering queries)
Study: 33856395
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (1 g every 6 hours for 48 hours)
Study: 33856395
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g every 6 hours for 48 hours)
Study: 34074289
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 12 weeks
Study: 33208583
Drug: Goreisan for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goreisan for 3 months (Group G)
Study: 33208583
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Group N)
Study: 33208583
Drug: Goreisan for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goreisan for 3 months (Group G) in high-risk patients
Study: 33208583
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Group N) in high-risk patients
Study: 36443869
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive behavioral therapy for insomnia (gCBT-I)
Study: 34588952
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day istradefylline
Study: 35448974
Drug: Resistance Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance Training (RT) for 12 weeks, coupled with Behavioral Activation techniques, meeting twice/week.
Study: 35448974
Drug: Attention-control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-control group (Health, Wellness, and Education; HWE) for 12 weeks, meeting twice/week.
Study: 33634552
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral clindamycin plus rifampicin (C + R)
Study: 33634552
Drug: Oral clindamycin
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clindamycin monotherapy (CM)
Study: 33710319
Drug: β-blocker prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker prescription
Study: 35887551
Drug: Iloprost (ILO)
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost (ILO) inhalation
Study: 32533427
Drug: Insulin loading
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin loading procedure
Study: 33797658
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis of analgesics (meloxicam, celecoxib, rofecoxib)
Study: 34455503
Drug: Tilted group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilted group implants (2 anterior axial and 2 posterior distally inclined implants)
Study: 34455503
Drug: Axial group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axial group implants (2 implants in the interforaminal area and 2 in the molar area)
Study: 33326656
Drug: Withdrawal combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal combined with preventive medication (W+P)
Study: 33326656
Drug: Withdrawal with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal with optional preventive medication (W)
Study: 33326656
Drug: Preventive medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive medication without withdrawal (P)
Study: 33529350
Drug: Sunscreens and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreens and cosmetic formulations containing ascorbyl tetraisopalmitate and rice peptides
Study: 35428613
Drug: Co-amoxiclav 400/57
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 400/57 suspension
Study: 32252680
Drug: Concurrent EP
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent EP (etoposide + cisplatin) chemotherapy with intensity-modulated radiation therapy (IMRT)
Study: 32252680
Drug: Concurrent PC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent PC (paclitaxel + carboplatin) chemotherapy with intensity-modulated radiation therapy (IMRT)
Study: 35945745
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with intravenous ibuprofen (10 mg/kg) administered once within 6 hours after birth
Study: 35945745
Drug: Non-prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prophylactic treatment (non-PT)
Study: 35945745
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with intravenous ibuprofen (10 mg/kg)
Study: 34911530
Drug: Conventional non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-surgical therapy (CNST)
Study: 33604941
Drug: Twice-daily regimen
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily regimen (UFT 300 mg/m2 per day, LV 50 mg per day)
Study: 33604941
Drug: Three-times-daily regimen
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times-daily regimen (UFT 300 mg/m2 per day, LV 75 mg per day)
Study: 35927627
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic conditioning (RIC) + best medical treatment (BMT)
Study: 34324933
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 μg.kg-1) followed by propofol (1 mg.kg-1) after 1 minute
Study: 34324933
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 μg.kg-1) followed by propofol (2 mg.kg-1) after 2 minutes
Study: 34324933
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (1 min and 2 min with varying doses of propofol)
Study: 32167611
Drug: Full-energy enteral
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-energy enteral feeding starting at 75% of daily energy expenditure, increasing to 90%-100%.
Study: 32167611
Drug: Hypocaloric enteral
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric enteral feeding starting with 30% of daily energy expenditure, reaching 75% within 7 days.
Study: 35176136
Drug: Both Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Both Bevacizumab and Cetuximab plus chemotherapy
Study: 34706141
Drug: Sunitinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib treatment duration in immediate arm
Study: 34706141
Drug: Sunitinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib treatment duration in deferred arm
Study: 34545166
Drug: Treatment-as-usual comparison
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual comparison group
Study: 36420043
Drug: infant standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: infant standard therapy
Study: 35448895
Drug: Intracavernosal incobotulinumtoxinA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal incobotulinumtoxinA (Xeomin®) 100 U as an add-on therapy
Study: 33529664
Drug: Apixaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (2.5 mg dose)
Study: 34986793
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received CFNB and sciatic nerve block with 0.16% levobupivacaine and 6 mg indigo carmine at 6 ml/h
Study: 32970172
Drug: β‐lactam antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐lactam antibiotic treatment for less than seven days
Study: 35583488
Drug: Anabolic-androgenic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic-androgenic steroids (AAS)
Study: 33627069
Drug: FindMyApps intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FindMyApps intervention (tablet computer and FindMyApps)
Study: 33627069
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (control arm - tablet computer)
Study: 35215431
Drug: 50% taro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% taro flour + 50% wheat flour + probiotic L. plantarum IS‐10506
Study: 32719251
Drug: Ayurvedic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic preparation Yashtimadhu in addition to conventional treatment
Study: 32719251
Drug: Conventional mucositis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mucositis treatment
Study: 32719251
Drug: Honey for
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey for local application and oral intake in addition to routine conventional treatment
Study: 33621332
Drug: Meditation and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meditation and Exercise Treatment (MedExT)
Study: 34712343
Drug: Harpagophytum procumbens
Normalized name: Harpagophytum procumbens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harpagophytum procumbens (Teltonal) 2 tablets (2*480 mg) daily for one month
Study: 34712343
Drug: meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 15 mg daily for ten days
Study: 34010183
Drug: ACEI/ARB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB treatment after PCI
Study: 34010183
Drug: ACEI/ARB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB treatment after CABG
Study: 34010183
Drug: No ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACEI/ARB treatment after PCI
Study: 34010183
Drug: No ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACEI/ARB treatment after CABG
Study: 34010183
Drug: No ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ACEI/ARB treatment
Study: 34949637
Drug: Two-stage consent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage consent pathway (oral assent followed by informed written consent)
Study: 36000981
Drug: ACT-1014-6470 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-1014-6470 (60 mg)
Study: 34536664
Drug: Cannabidiol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol (0.25 ml, 5% cannabidiol, 12.5 mg cannabidiol)
Study: 34174349
Drug: Mock (control)
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock (control) treatment
Study: 33095633
Drug: Certification methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certification methods for quantum state preparation and measurement devices
Study: 33879769
Drug: SEP-363856 50
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856 50 mg
Study: 33879769
Drug: SEP-363856 10
Normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856 10 mg
Study: 36344851
Drug: R0 resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R0 resection and lenvatinib-transarterial chemoembolization (lenvatinib-TACE) sequential therapy
Study: 36344851
Drug: Other non-curative-intent
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other non-curative-intent subsequent treatment
Study: 36344851
Drug: R0 resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R0 resection and lenvatinib-TACE sequential therapy
Study: 36344851
Drug: Non-curative-intent subsequent
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-curative-intent subsequent treatment
Study: 34981493
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil ointment (85% olive oil), applied twice a day for 4 days
Study: 34981493
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (85% liquid paraffin, similar in color and odor to olive oil ointment), applied twice a day for 4 days
Study: 32244028
Drug: Dengzhan Shengmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengzhan Shengmai (DZSM) capsules
Study: 33508236
Drug: Superficial nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial nerve block (SNB) with 1.8 mL of 2% lidocaine and 1:100,000 epinephrine
Study: 33508236
Drug: Conventional technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional technique (CT) with 1.8 mL of 2% lidocaine and 1:100,000 epinephrine
Study: 36441736
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (INI)
Study: 32969563
Drug: Cabozantinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (40 mg) plus docetaxel (75 mg/m2 every 3 weeks) and prednisone (10 mg daily)
Study: 32969563
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 every 3 weeks) and prednisone (10 mg daily) alone
Study: 35905636
Drug: Daily massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily massage therapy administered by the mother from 34 weeks' to 40 weeks' corrected age (CA)
Study: 34293233
Drug: Esketamine plus
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine plus oral antidepressant
Study: 34293233
Drug: Antidepressant/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant/placebo
Study: 34508886
Drug: 14-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day treatment
Study: 32388584
Drug: Enteric-coated NaHCO3
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated NaHCO3 (0.3 g∙kg‐1 body mass)
Study: 32388584
Drug: Gelatin NaHCO3
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gelatin NaHCO3 (0.3 g∙kg‐1 body mass)
Study: 32394874
Drug: Miltefosine monotherapy
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine monotherapy
Study: 36196796
Drug: Complex 1
Normalized name: B-COMPLEX 100 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex 1 ([Fe(L)][Fe(bpb)(CN)2]·CH3OH·0.5H2O)
Study: 36196796
Drug: Complex 2
Normalized name: hesperidin complex 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex 2 ([Fe(L)][Co(bpb)(CN)2]·CH3OH)
Study: 36196796
Drug: Complex 3
Normalized name: chlorophyllin copper complex 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex 3 ([(Fe (L))2(4,4'‐bipy)](BPh4)2)
Study: 36196796
Drug: Complex 4
Normalized name: polysaccharide iron complex 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex 4 ([Fe(L)(py)](BPh4))
Study: 36196796
Drug: Complex 5
Normalized name: B-Complex 50
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complex 5 ([Fe(L)(dmap)](BPh4))
Study: 32954451
Drug: Cypermethrin (CYP)
Normalized name: cypermethrin
DrugBank: Cypermethrin (DB13721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cypermethrin (CYP) treatment at 10 μg mL‐1
Study: 32954451
Drug: Cypermethrin (CYP)
Normalized name: cypermethrin
DrugBank: Cypermethrin (DB13721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cypermethrin (CYP) treatment